Your browser doesn't support javascript.
loading
Interferon-Beta Injection in Multiple Sclerosis Patients Related to the Induction of Headache and Flu-Like Pain Symptoms: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Pereira, Leonardo Gomes; Rodrigues, Patrícia; Viero, Fernanda Tibolla; Frare, Julia Maria; Ramanzini, Luís Guilherme; Trevisan, Gabriela.
Afiliação
  • Pereira LG; Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa Maria (UFSM), 97105-900 Santa Maria (RS), Brazil.
  • Rodrigues P; Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa Maria (UFSM), 97105-900 Santa Maria (RS), Brazil.
  • Viero FT; Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa Maria (UFSM), 97105-900 Santa Maria (RS), Brazil.
  • Frare JM; Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa Maria (UFSM), 97105-900 Santa Maria (RS), Brazil.
  • Ramanzini LG; Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa Maria (UFSM), 97105-900 Santa Maria (RS), Brazil.
  • Trevisan G; Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa Maria (UFSM), 97105-900 Santa Maria (RS), Brazil.
Curr Neuropharmacol ; 20(8): 1600-1612, 2022.
Article em En | MEDLINE | ID: mdl-34720084
ABSTRACT
Multiple sclerosis (MS) is a chronic neurodegenerative, inflammatory, and autoimmune disease characterised by the demyelination of the central nervous system. One of the main approaches for treating MS is the use of disease-modifying therapies (DMTs). Among the DMTs are interferons (IFNs), which are cytokines responsible for controlling the activity of the immune system while exerting immunomodulatory, antiviral, and antiproliferative activities. IFN-beta (IFN-ß) is the first-choice drug used to treat relapsing-remitting MS. However, the administration of IFN-ß causes numerous painful adverse effects, resulting in lower adherence to the treatment. Therefore, this study aimed to investigate the headache and flu-like pain symptoms observed after IFNß injection in MS patients using a systematic review and meta-analysis of randomised controlled trials. A total of 2370 articles were identified through research databases. Nine articles were included (three involving IFNß-1b and six involving IFNß-1a). All studies included in the meta-analysis had a low risk of bias. The odds ratio of headache and flu-like pain symptoms increased in MS patients treated with IFN-ß. Thus, the adverse effects of headache and flu-like pain symptoms appear to be linked to IFN-ß treatment in MS. The protocol of the study was registered in the Prospective International Registry of Systematic Reviews (registration number CRD42021227593).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Interferon beta / Cefaleia / Esclerose Múltipla Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Systematic_reviews Limite: Humans Idioma: En Revista: Curr Neuropharmacol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Interferon beta / Cefaleia / Esclerose Múltipla Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Systematic_reviews Limite: Humans Idioma: En Revista: Curr Neuropharmacol Ano de publicação: 2022 Tipo de documento: Article